CTOR Citius Oncology, Inc. Common Stock
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CTOR
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- List Date
- 2024-08-13
- CIK
- 0001851484
- Headquarters
- Cranford, NJ
- Homepage
- https://www.citiusonc.com
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | 0.92% | -1.85% | -0.47% |
| Feb | -- | -2.79% | 3.70% | 0.46% |
| Mar | -- | -10.58% | -42.60% | -26.59% |
| Apr | -- | 0.95% | 35.77% | 18.36% |
| May | -- | 1.12% | -15.55% | -7.21% |
| Jun | -- | 388.71% | -17.95% | 185.38% |
| Jul | -- | -57.42% | -15.41% | -36.41% |
| Aug | -44.69% | 5.34% | 22.03% | -5.77% |
| Sep | -18.24% | 1.00% | 34.67% | 5.81% |
| Oct | -12.22% | -11.17% | -39.21%* | -20.87% |
| Nov | -19.38% | -17.96% | -- | -18.67% |
| Dec | 12.75% | -39.02% | -- | -13.14% |
| Total | -63.92% | -11.89% | -53.55% | -43.12% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.80
SMA 50: $0.85
SMA 200: $0.85
Current: $0.60
EMA 12: $0.72
EMA 26: $0.79
MACD: -0.0745 | Signal: -0.0264
BEARISH
ADX (14): 35.75
TREND
+DI: 6.58
−DI: 25.39
Momentum Oscillators
RSI (14): 28.62
OVERSOLD
Stoch %K: 18.62
Stoch %D: 14.84
Williams %R: -78.10
Volume & Volatility
BB Upper: $1.06
BB Lower: $0.55
NEUTRAL
OBV: 274,785,189
Vol SMA 20: 119,286
Vol ROC: 1186.41%
ATR: $0.09
True Range: $0.15
HV 20: 80.9%
HV 30: 96.9%
HV 60: 102.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: CTOR
Executive Summary
Overall Assessment: NEUTRAL (6/10)
The stock's technical indicators suggest a neutral sentiment, with the MACD indicating bearish momentum. The RSI is at 35.56, suggesting a neutral reading. The Bollinger Bands are contracting, which may indicate a potential breakout or mean reversion. Recent news headlines have been positive, but the overall market and sector performance suggest a cautious approach.
Key Drivers: Positive news sentiment from recent announcements about LYMPHIR's successful launch and financing rounds.
Primary Risks:
- High Volatility: Beta of 2.00 indicates high risk relative to the market.
- Bearish Momentum: MACD indicates bearish momentum, which may lead to further price declines.
- Lack of Earnings Data: No recent earnings data available, making it difficult to assess financial performance.
Investment Thesis: CTOR's stock price may experience a correction due to the negative trend indicators and high volatility. However, the positive news sentiment and successful launch of LYMPHIR may lead to a mean reversion or breakout in the short term.
Recent News Sentiment Impact: Positive news headlines have contributed to the recent price increase, but the overall market and sector performance suggest caution.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Downtrend
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels: Key levels to monitor include the SMA 20 ($0.77) and SMA 50 ($0.83).
Momentum Signals:
- RSI interpretation: Neutral (35.56)
- MACD signal: Bearish
- Bollinger Bands position: Contracting, indicating a potential mean reversion or breakout
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines about LYMPHIR's successful launch and financing rounds.
Sentiment Assessment: Aggregate sentiment is positive (4/5).
Catalyst Identification: Upcoming earnings report (if available) may provide additional information on the company's financial performance.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the market (beta = 2.00).
Volatility Regime: Current volatility is higher than historical levels.
Options Market Signals: No options data available.
Downside Protection: SMA 20 ($0.77) and SMA 50 ($0.83) serve as support levels.
Market Context & Positioning
Sector Performance: Weak performance compared to the broader market.
Institutional Activity: Low institutional interest based on volume patterns.
Correlation Analysis: Stock moves more than the market (R-squared = 0.19).
Relative Valuation: Stock is trading within its historical range.
Key Levels & Action Items
Critical Price Levels: SMA 20 ($0.77) and SMA 50 ($0.83) are key support levels to monitor.
Breakout/Breakdown Levels: Upper Bollinger Band ($0.90) may serve as a potential breakout level, while the lower band ($0.63) could indicate a potential breakdown.
Time-Sensitive Catalysts: Earnings report (if available) and regulatory updates may provide additional information on the company's financial performance.
Risk Management: Consider stop-loss levels around SMA 20 ($0.77) and position sizing considerations based on the stock's volatility.
Generated
News
All CTOR news →
CTOR Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.7943
Alpha: -86.80%
Correlation: 0.2454
R-Squared: 6.0%
Stock Volatility: 93.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CTOR
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $59K | #5964 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CTOR Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
CTOR Insider Trading (Form 4)
Latest: 2025-12-22Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Jaime Bartushak | Chief Financial Officer | Award (A) | +825,000 | — | EDGAR | |
| 2025-12-22 | Robert Joseph Smith | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-22 | Suren G Dutia | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-22 | Leonard L Mazur | Chief Executive Officer | Award (A) | +1,700,000 | — | EDGAR | |
| 2025-12-22 | Myron Z Holubiak | Secretary | Award (A) | +850,000 | — | EDGAR | |
| 2025-12-22 | Carol Webb | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-22 | Joel David Mayersohn | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-22 | Eugene Myron Holuka | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-22 | Myron Czuczman | Chief Medical Officer | Award (A) | +825,000 | — | EDGAR | |
| 2025-12-22 | Dennis M McGrath | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-01 | Carol Webb | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-01 | Myron Z Holubiak | Secretary | Award (A) | +850,000 | — | EDGAR | |
| 2025-12-01 | Myron Czuczman | Chief Medical Officer | Award (A) | +825,000 | — | EDGAR | |
| 2025-12-01 | Dennis M McGrath | Director | Award (A) | +300,000 | — | EDGAR | |
| 2025-12-01 | Joel David Mayersohn | Director | Award (A) | +300,000 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CTOR Insider Holdings
10 insiders · @ $0.60
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Leonard L Mazur | Chief Executive Officer | 1,700,000 | $1.01M | $0 | 5 | 2025-12-22 |
| 2 | Myron Z Holubiak | Secretary | 950,000 | $565.9K | $0 | 5 | 2025-12-22 |
| 3 | Jaime Bartushak | Chief Financial Officer | 825,000 | $491.5K | $0 | 5 | 2025-12-22 |
| 4 | Myron Czuczman | Chief Medical Officer | 825,000 | $491.5K | $0 | 5 | 2025-12-22 |
| 5 | Joel David Mayersohn | Director | 321,228 | $191.4K | $0 | 5 | 2025-12-22 |
| 6 | Dennis M McGrath | Director | 300,000 | $178.7K | $0 | 4 | 2025-12-22 |
| 7 | Suren G Dutia | Director | 300,000 | $178.7K | $0 | 4 | 2025-12-22 |
| 8 | Carol Webb | Director | 300,000 | $178.7K | $0 | 4 | 2025-12-22 |
| 9 | Eugene Myron Holuka | Director | 300,000 | $178.7K | $0 | 5 | 2025-12-22 |
| 10 | Robert Joseph Smith | Director | 300,000 | $178.7K | $0 | 4 | 2025-12-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CTOR Board & Officers
As of SEC filings through Aug 14, 2026Directors 9
- Joel David Mayersohn · since Oct 13, 2022
- Carol Webb · since Aug 12, 2024
- Dennis M McGrath · since Aug 12, 2024
- Eugene Myron Holuka · since Aug 12, 2024
- Leonard L Mazur · since Aug 12, 2024
- Myron Z Holubiak · since Aug 12, 2024
- Robert Joseph Smith · since Aug 12, 2024
- Suren G Dutia · since Aug 12, 2024
- Jonathan Peri · since Aug 10, 2026
Officers 4
- Leonard L Mazur · Chief Executive Officer · since Aug 12, 2024
- Jaime Bartushak · Chief Financial Officer · since Aug 12, 2024
- Myron Czuczman · Chief Medical Officer · since Aug 12, 2024
- Myron Z Holubiak · Secretary · listed since Dec 2024
Changes in the last 10 years (23)
| Aug 10, 2026 | Jonathan Peri became a director |
| Dec 16, 2024 | Myron Z Holubiak first listed as Secretary in an SEC filing |
| Aug 12, 2024 | Suren G Dutia became a director |
| Aug 12, 2024 | Robert Joseph Smith became a director |
| Aug 12, 2024 | Myron Z Holubiak became a director |
| Aug 12, 2024 | Myron Czuczman became Chief Medical Officer |
| Aug 12, 2024 | Leonard L Mazur became a director |
| Aug 12, 2024 | Leonard L Mazur became Chief Executive Officer |
| Aug 12, 2024 | Jaime Bartushak became Chief Financial Officer |
| Aug 12, 2024 | Eugene Myron Holuka became a director |
| Aug 12, 2024 | Dennis M McGrath became a director |
| Aug 12, 2024 | Citius Pharmaceuticals, Inc. became a 10% owner |
| Aug 12, 2024 | Carol Webb became a director |
| Oct 13, 2022 | Xiaofeng Yuan became a director |
| Oct 13, 2022 | Xiaofeng Yuan became a 10% owner |
| Oct 13, 2022 | Xiaofeng Yuan became Chief Executive Officer |
| Oct 13, 2022 | Joel David Mayersohn became a director |
| Oct 13, 2022 | Dahe Zhang became a director |
| Oct 13, 2022 | Dahe Zhang became a 10% owner |
| Oct 13, 2022 | Dahe Zhang became Chief Financial Officer |
| Oct 13, 2022 | Cathy Jiang became a director |
| Oct 13, 2022 | Brian Shawn Hartzband became a director |
| Oct 13, 2022 | 10XYZ Management LLC became a 10% owner |
Not reported recently (6)
- Citius Pharmaceuticals, Inc. · Last reported as a 10% owner in an SEC filing dated Aug 14, 2024
- Cathy Jiang · Last reported as a director in an SEC filing dated Oct 13, 2022
- 10XYZ Management LLC · Last reported as a 10% owner in an SEC filing dated Oct 13, 2022
- Xiaofeng Yuan · Last reported as a director in an SEC filing dated Oct 13, 2022
- Dahe Zhang · Last reported as a director in an SEC filing dated Oct 13, 2022
- Brian Shawn Hartzband · Last reported as a director in an SEC filing dated Oct 13, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
2 ETFs hold CTOR
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.